Johanna Friedl-Naderer is a seasoned biotechnology executive with over two decades of experience in commercial strategy, product launches, and market access for rare diseases and gene therapies. She began her career at Bayer HealthCare, advancing through roles in marketing and sales before joining Novartis in 2013. At Novartis, she held progressively senior positions, including Vice President of Global Marketing for Gene & Cell Therapy and Head of Global Commercial Strategy for Innovative Medicines, where she spearheaded the commercialization of breakthrough therapies in hematology and immunology, driving significant revenue growth and global market penetration. In 2021, Friedl-Naderer became Chief Commercial Officer at bluebird bio, leading the launches of ZYNTEGLO and SKYSONA, the company's first approved gene therapies for beta-thalassemia, transfusion-dependent beta-thalassemia, and cerebral adrenoleukodystrophy. Her strategic oversight resulted in successful payer negotiations, expanded reimbursement coverage, and the establishment of innovative patient support programs, positioning bluebird as a leader in the gene therapy space despite market challenges. Appointed Chief Commercial Officer at Dyne Therapeutics Inc. in 2023, Friedl-Naderer now drives the company's commercial vision for its FORCE platform, targeting muscle diseases like Duchenne muscular dystrophy. She oversees global commercialization strategy, market access, and partnerships, preparing for potential launches of Dyne's pipeline candidates, including DYNE-101 and DYNE-251. Her expertise in rare disease ecosystems and proven track record in high-unmet-need therapies position her to accelerate Dyne's mission of delivering transformative Olympic-level medicines to patients worldwide.